Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesCardiologyParkland Farxiga Pediatric Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentParkland Community Health PlanPolicy N/A

    Medical Necessity Determination and Appeal Overturn Policy for Off-Label Use of Farxiga (Dapagliflozin) in Pediatric Members with Heart Failure and Complex Cardiac Conditions

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity determinations and appeal overturns for off-label dapagliflozin (Farxiga) in members younger than 18 years with heart failure and complex cardiac conditions enrolled in STAR and CHIP benefit plans.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyOff-label Farxiga coverage appeals in pediatric heart failure
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJun 26, 2026
    Next Review DateN/A
    Key ActionDocument optimized guideline-directed medical therapy appropriate to the member’s age and physiology before approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <18 yearsMember age requirement
    6Coverage criteria categories
    3-6 monthsAuthorization period
    STAR and CHIP

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Benefit plans
    4Qualifying cardiac pathways

    Coverage Criteria

    Initial appeal approval

    Coverage may be approved on appeal when ALL of the following criteria are met.

    • Diagnosis

      • Symptomatic systolic heart failure with Ross or NYHA Class II-IV symptoms.Ross or NYHA Class II-IV
      • Post-transplant heart failure: Post-heart-transplant graft dysfunction with heart failure.
      • Complex congenital heart disease, such as unbalanced atrioventricular canal, with documented ventricular dysfunction.
      • Tracheobronchomalacia with cardiac instability: Tracheobronchomalacia with objective evidence that heart failure is contributing to clinical instability.
    • Disease severity: The member has NYHA or Ross Class II-IV symptoms and objective evidence of ventricular dysfunction by echocardiography or cardiac MRI; elevated natriuretic peptides are included when available.NYHA/Ross Class II-IV

      Natriuretic peptides are required only if available.

    • Failure or optimization of standard therapy: Documentation shows optimized guideline-directed medical therapy appropriate to the member's age and physiology, including ACE inhibitor/ARB or ARNI if tolerated, beta-blocker if appropriate, diuretics, mineralocorticoid receptor antagonist if indicated, and device therapy when clinically indicated.

      Therapies are conditional when indicated or tolerated.

    • Prescriber requirements: The member is managed by a board-certified pediatric cardiologist or pediatric heart failure/transplant specialist.
    • Safety and monitoring: The member has no history of recurrent diabetic ketoacidosis, has a baseline renal-function assessment, has no severe age-adjusted renal impairment, and has a monitoring plan for volume status, renal function, and ketosis.

    Continuation therapy

    Continued therapy requires all listed documentation elements.

    Continuation therapy: For continued therapy, documentation must show clinical improvement or stabilization, absence of serious adverse effects, and ongoing specialist management.Re-approval for 3-6 months

    Initial authorization and re-approval are for 3-6 months.

    This policy does not apply to FDA-approved indications for dapagliflozin.

    This policy does not apply to adult members aged 18 years or older.

    Provider Documentation and Decision Points

    Prior Authorization

    Appeal Approval Requires All Criteria

    Coverage may be approved on appeal only when all applicable criteria are met for an eligible pediatric member with heart failure or a qualifying complex cardiac condition. The provider must submit complete documentation addressing diagnosis, disease severity, optimized therapy, specialist management, and safety monitoring.

    • Appeal approval requires satisfaction of every applicable coverage criterion; partial documentation does not support approval.
    Documentation Required

    Document Optimized Guideline-Directed Therapy

    Document optimized, age- and physiology-appropriate guideline-directed medical therapy before requesting off-label dapagliflozin.

    • ACE inhibitor, ARB, or ARNI if tolerated
    • Beta-blocker when appropriate
    • Diuretics

    Policy Background

    This policy addresses off-label dapagliflozin use in pediatric members with heart failure and complex cardiac conditions. The scope includes systolic heart failure, post-heart-transplant heart failure or graft dysfunction, congenital heart disease including unbalanced atrioventricular canal, and tracheobronchomalacia when associated with documented cardiac-related heart failure.

    Clinical Definitions

    AVC (Atrioventricular Canal)
    AcronymAVC
    Expanded termAtrioventricular Canal
    Clinical definitionA congenital heart defect involving abnormalities of the atrial and ventricular septa and atrioventricular valves.
    CHD (Congenital Heart Disease)
    AcronymCHD
    Expanded termCongenital Heart Disease
    Clinical definitionStructural heart abnormalities present at birth.
    Policy Summary
    PayerParkland Community Health Plan
    PolicyOff-label Farxiga coverage appeals in pediatric heart failure
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJun 26, 2026
    Next Review DateN/A
    Key ActionDocument optimized guideline-directed medical therapy appropriate to the member’s age and physiology before approval.
    SourceLink
    On This Page
    Coverage CriteriaProvider Documentation and Decision PointsPolicy BackgroundClinical Definitions
  1. Mineralocorticoid receptor antagonist when indicated
  2. Device therapy when clinically indicated
  3. Documentation Required

    Document Diagnosis and Disease Severity

    Submit documentation confirming that the member is younger than 18 and has a qualifying diagnosis with clinically significant disease. Include functional class and objective evidence of severity when available.

    • Symptomatic systolic heart failure, Ross or NYHA Class II-IV
    • Post-heart-transplant graft dysfunction with heart failure
    • Complex congenital heart disease, such as unbalanced atrioventricular canal, with documented ventricular dysfunction
    • Tracheobronchomalacia with objective evidence that heart failure contributes to clinical instability
    • Objective ventricular dysfunction on echocardiography or MRI and elevated natriuretic peptides, if available
    Step Therapy

    Document Failure or Optimization of Standard Therapy

    Show that standard therapy has been optimized for the member’s age, physiology, and clinical condition, including the rationale for any therapy that is not tolerated, not appropriate, or not indicated.

    • Document the current regimen, treatment response, and relevant contraindications or intolerance.
    • Document device therapy when clinically indicated.

    Unsupported block type: documentation

    Documentation Required

    Complete Safety Documentation

    Provide safety documentation before approval, including baseline renal assessment and a plan to monitor volume status, renal function, and ketosis.

    • Confirm no history of recurrent diabetic ketoacidosis (DKA).
    • Confirm no severe age-adjusted renal impairment.
    • Document baseline renal function.
    • Provide a monitoring plan for volume status, renal function, and ketosis.
    Prior Authorization

    Continuation Documentation Required

    For re-approval, document that therapy remains clinically appropriate and safe and that specialist management continues.

    • Clinical improvement or stabilization
    • Absence of serious adverse effects
    • Ongoing pediatric cardiology or pediatric heart-failure/transplant specialist management
    • Re-approval is for 3-6 months when continuation criteria are met.
    Denial Risk

    Failure to Meet Coverage Criteria

    An appeal may be denied when the request does not establish the required pediatric diagnosis, disease severity, optimized standard therapy, specialist management, or safety documentation. Missing, contradictory, or insufficient records do not demonstrate that all criteria are met.

    • No qualifying pediatric cardiac diagnosis or documented heart-failure contribution
    • Functional class or objective ventricular dysfunction is not documented
    • Optimized age- and physiology-appropriate therapy is not documented
    • Required pediatric specialist management is absent
    • Required renal, DKA, or monitoring documentation is incomplete
    Denial Risk

    Out-of-Scope Request

    This policy is limited to pediatric STAR and CHIP members receiving off-label dapagliflozin for the specified cardiac-related conditions. Requests for adult members or for FDA-approved indications are outside the scope of this policy.

    • Adult members age 18 years or older are out of scope.
    • FDA-approved indications are out of scope.
    • The policy applies to pediatric systolic heart failure, post-heart-transplant heart failure or graft dysfunction, qualifying complex congenital heart disease, and tracheobronchomalacia associated with documented cardiac-related heart failure.
    Denial Risk

    Safety Concerns May Prevent Approval

    Safety concerns must be resolved and documented before approval. Recurrent DKA, severe age-adjusted renal impairment, or inability to monitor the member creates a safety risk and may support denial.

    • Recurrent diabetic ketoacidosis
    • Severe age-adjusted renal impairment
    • No adequate plan to monitor volume status, renal function, and ketosis
    Denial Risk

    Insufficient Continuation Documentation

    Continuation or re-approval may be denied when the record does not sufficiently demonstrate ongoing benefit, safety, monitoring, or specialist management.

    • Clinical improvement or stabilization is not documented.
    • Serious adverse effects or ongoing safety concerns are not addressed.
    • Required monitoring is incomplete or absent.
    • Ongoing pediatric cardiology or pediatric heart-failure/transplant specialist management is not documented.
    GDMT (Guideline-Directed Medical Therapy)
    AcronymGDMT
    Expanded termGuideline-Directed Medical Therapy
    Clinical definitionEvidence-based pharmacologic and device therapy recommended in national cardiology guidelines.
    HF (Heart Failure)
    AcronymHF
    Expanded termHeart Failure
    Clinical definitionA clinical syndrome characterized by symptoms and signs resulting from impaired ventricular filling or ejection of blood.
    HFrEF (Heart Failure with Reduced Ejection Fraction)
    AcronymHFrEF
    Expanded termHeart Failure with Reduced Ejection Fraction
    Clinical definitionSystolic heart failure typically defined by reduced ventricular ejection fraction.
    NYHA (New York Heart Association) Functional Classification
    AcronymNYHA
    Expanded termNew York Heart Association Functional Classification
    Clinical definitionA classification system describing heart-failure symptom severity.
    Ross Classification
    Classification nameRoss Classification
    Clinical contextPediatric functional classification system
    Clinical definitionA pediatric functional classification system for heart-failure severity.
    SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor
    AcronymSGLT2
    Expanded termSodium-Glucose Cotransporter-2 Inhibitor
    Clinical definitionA class of medications that inhibit renal glucose reabsorption and exert natriuretic and cardiometabolic effects.